Learn Peptide
Peptide Directory

Category · 23 peptides

Growth Hormone & Performance

GHRH, GHRP/ghrelin secretagogues, and IGF peptides studied for GH release, recovery, and body composition.

ACE-031Emerging
A soluble decoy receptor fusion protein that sequesters myostatin and related muscle-suppressing ligands to release multiple brakes on muscle and bone growth at once.
  • Myostatin and activin inhibition
  • Increased lean muscle mass
  • Improved bone density
1 studies
CJC-1295 (no DAC)Emerging
A short-acting, DPP-4-resistant GHRH analog that drives sharp, physiologic pulses of the body's own growth hormone.
  • Pulsatile GH release
  • Strong synergy with ghrelin-receptor agonists
  • Downstream IGF-1 elevation
4 studiesdosing4 stacks
CJC-1295 + Ipamorelin BlendEmerging
The clinic-standard GH-axis pairing that combines a GHRH analog and a selective GHRP in one vial to amplify the body's own growth hormone pulses through two separate receptors.
  • Synergistic GH pulse amplification
  • Improved sleep depth
  • Training recovery
1 studiesdosing2 stacks
CJC-1295 DACEmerging
A long-acting GHRH analog whose Drug Affinity Complex binds albumin to stretch its half-life to roughly a week, producing sustained GH and IGF-1 elevation from a single weekly injection.
  • Sustained GH and IGF-1 elevation
  • Once-weekly dosing convenience
  • Endogenous GH stimulation
1 studiesdosing3 stacks
Follistatin 344Preclinical
A 344-amino-acid recombinant follistatin isoform that sequesters myostatin and activin A to release the natural brake on skeletal muscle growth.
  • Dual TGF-beta inhibition (myostatin + activin A)
  • Skeletal muscle hypertrophy (animal models)
  • Satellite cell activation and protein synthesis
2 studiesdosing2 stacks
GhrelinEmerging
The body's endogenous 'hunger hormone' and natural ligand for the growth hormone secretagogue receptor, driving both GH release and appetite.
  • Growth hormone stimulation
  • Appetite stimulation
  • Metabolic regulation
9 studies
GHRP-2Moderate
A first-generation synthetic hexapeptide ghrelin-receptor agonist that drives potent pulsatile growth hormone release, at the cost of modest cortisol, prolactin, and appetite stimulation.
  • Potent pulsatile GH release
  • Downstream IGF-1 elevation for body composition
  • Synergy with GHRH analogs
2 studiesdosing4 stacks
GHRP-6Emerging
The original ghrelin-receptor GH secretagogue, distinguished by the strongest appetite stimulation of the GHRP class.
  • Pulsatile growth hormone release
  • Pronounced appetite stimulation
  • Muscle recovery and body composition support
2 studiesdosing3 stacks
HexarelinEmerging
The most potent growth hormone secretagogue in the GHRP class, with a unique CD36-mediated cardioprotective mechanism separate from its GH-releasing activity.
  • Maximum GH pulse amplitude
  • Synergy with GHRH
  • Cardioprotective CD36 activity
2 studiesdosing3 stacks
HGH (Somatropin)FDA-Approved
The original recombinant anabolic peptide drug: a 191-amino-acid copy of human growth hormone, FDA-approved for decades in true deficiency and heavily criminalized off-label.
  • Treats pediatric growth failure
  • Treats adult GH deficiency
  • Increases lean mass and reduces fat
3 studiesdosing
IGF-1Emerging
The liver-derived 70-amino-acid polypeptide that serves as the principal mediator of growth hormone's anabolic effects on muscle, bone, and tissue.
  • Muscle growth and protein synthesis
  • Recovery and tissue repair
  • Bone growth
8 studies
IGF-1 DESPreclinical
A truncated IGF-1 variant missing its first three amino acids, trading systemic reach for potent, short-lived anabolic action at the injection site.
  • Higher local anabolic potency
  • Site-specific muscle hypertrophy
  • Activation of protein-synthesis signaling
dosing3 stacks
IGF-1 LR3Preclinical
A long-acting synthetic IGF-1 analog engineered to escape binding-protein control and drive sustained, supraphysiologic IGF-1 receptor signaling for muscle growth.
  • Muscle protein synthesis and hypertrophy
  • Satellite cell activation and tissue repair
  • Extended, sustained IGF-1 signaling
2 studiesdosing4 stacks
IGF-2Emerging
An endogenous embryonic growth factor and IGF-1 relative that acts as an autocrine driver of muscle cell differentiation through the IGF-1 receptor.
  • Skeletal muscle differentiation
  • Anabolic signaling via IGF-1R
  • Counteracting muscle-wasting signals
7 studies
IpamorelinEmerging
The cleanest of the growth hormone-releasing peptides: a selective ghrelin-receptor agonist that triggers a natural GH pulse without spiking cortisol, prolactin, or ACTH.
  • Selective GH release without stress-hormone burden
  • Preserves natural pulsatile GH architecture
  • IGF-1 elevation and body composition support
4 studiesdosing5 stacks
MGFPreclinical
A locally acting IGF-1 splice variant that switches muscle satellite cells out of quiescence to drive the earliest phase of muscle repair after mechanical loading.
  • Satellite cell activation
  • Local autocrine/paracrine repair signal
  • Progenitor cell proliferation and fusion
2 studiesdosing2 stacks
MK-677 (Ibutamoren)Moderate
An orally active, non-peptide ghrelin receptor agonist that drives sustained growth hormone and IGF-1 elevation from a single daily dose.
  • Oral GH and IGF-1 stimulation without injection
  • Sustained IGF-1 elevation
  • Increased fat-free mass
4 studiesdosing3 stacks
Myostatin PropeptidePreclinical
The endogenous N-terminal prodomain of myostatin (GDF-8) that neutralizes mature myostatin to release the brakes on skeletal muscle growth.
  • Myostatin inhibition
  • Skeletal muscle hypertrophy
  • Lean mass increase
2 studies
PEG-MGFPreclinical
A PEGylated version of Mechano Growth Factor engineered to extend the muscle-satellite-cell-activating action of the IGF-1 splice variant from minutes to days.
  • Satellite cell activation and myonuclear accretion
  • Accelerated muscle repair and recovery
  • Extended systemic activity vs native MGF
dosing1 stacks
SermorelinEstablished
The original FDA-approved GHRH analog that stimulates the pituitary to release growth hormone in a natural, pulsatile pattern.
  • Natural pulsatile GH stimulation
  • Improved sleep quality and slow-wave sleep
  • Body composition improvement
3 studiesdosing4 stacks
Sermorelin + GHRP BlendModerate
The legacy GH-axis pairing that predates the clean ipamorelin stacks, combining a GHRH analog with a non-selective ghrelin-receptor agonist to amplify the growth hormone pulse.
  • Synergistic growth hormone release
  • Sustained IGF-1 elevation
  • Robust, low-cost secretagogue response
6 studiesdosing2 stacks
TesamorelinFDA-Approved
The only FDA-approved GHRH analog, engineered to stimulate the body's own pulsatile growth hormone release and selectively strip away deep visceral abdominal fat.
  • Visceral fat reduction
  • Selective sparing of subcutaneous fat
  • Hepatic (liver) fat reduction
6 studiesdosing3 stacks
Tesamorelin + Ipamorelin BlendModerate
A GH-axis pairing built on tesamorelin, the only GHRH analog with a full FDA approval, run alongside the cleanly selective GHRP ipamorelin.
  • Synergistic growth-hormone release
  • Selective visceral-fat reduction (tesamorelin arm)
  • Clean GHRP signaling (ipamorelin arm)
3 studiesdosing2 stacks
Noxa Labs — #1 research peptide supplier in the Philippines. Lab tested in CZ & USA, same-day Manila shipping. Save 15% with code LEARNPEPTIDE.